Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by Interferon-β gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1258-1270

  Izawa, Jonathan I ^a   Sweeney, Paul ^a   Perrotte, Paul ^a   Kedar, Daniel ^a   Dong, Zhongyun ^a   Slaton, Joel W ^a   Karashima, Takashi ^a   Inoue, Keji ^b   Benedict, William F ^a   Dinney, Colin P N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; CD31 ANTIGEN; GELATINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CARCINOGENICITY; CELL ACTIVATION; CONTROLLED STUDY; EFFECTOR CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPECIES DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TUMOR NECROSIS;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERFERON-BETA; INTERLEUKIN-8; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036554710     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA - Cancer J. Clin., 50: 7-33, 2000.
2. Hsieh, J., Dinney, C. P. N., and Chung, L. W. K. The potential role of gene therapy in the treatment of bladder cancer. Urol. Clin. N. Am., 27: 103-113, 2000.
3. Dalbagni, G., and Herr, H. W. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol. Clin. N. Am., 27: 137-146, 2000.
4. Lerner, S. P., and Skinner, D. G. Radical cystectomy for bladder cancer. In: N. J. Vogelzang, P. T. Scardino, W. U. Shipley, and D. S. Coffey (eds.), Genitourinary Oncology, pp. 425-447. Philadelphia: Lippincott Williams & Wilkins, 2000.
5. Kong, H., and Crystal, R. G. Gene therapy strategies for tumor angiogenesis. J. Natl. Cancer Inst. (Bethesda), 90: 273-286, 1998.
6. Tanaka, T., Cao, Y., Folkman, J., and Fine, H. A. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res., 58: 3362-3369, 1998.
7. Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L., and Terwilliger, E. F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res., 58: 5673-5677, 1998.
8. Singh, R. K., Bucana, C. D., Llansa, N., Sanchez, R., and Fidler, I. J. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β. Int. J. Oncol., 8: 649-656, 1996.
9. Dong, Z., Greene, G., Pettaway, C., Dinney, C. P. N., Eue, I., Lu, W., Bucana, C. D., Balbay, M. D., Bielenberg, D., and Fidler, I. J. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res., 59: 872-879, 1999.
10. Baron, S., and Dianzani, F. The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res., 24: 97-110, 1994.
11. Hertzog, P. J., Hwang, S. Y., and Kola, I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev., 39: 226-232, 1994.
12. Krown, S. E. Interferons in malignancy: biological products or biological response modifiers? J. Natl. Cancer Inst. (Bethesda), 80: 306-309, 1988.
13. Thomas, H., and Balkwill, F. R. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol. Ther., 52: 307-314, 1991.
14. Singh, R. K., Bucana, C. D., Gutman, M., Fan, D., Wilson, M. R., and Fidler, I. J. Organ-site dependent expression of bFGF in human renal cell carcinoma cells. Am. J. Pathol., 145: 365-374, 1994.
15. Vermeulen, P. B., Diriz, L. Y., Martin, M., Lemmens, J., and Van Oosterom, A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with-interferon-α-2b. J. Natl. Cancer Inst. (Bethesda), 89: 1316-1317, 1997.
16. Dinney, C. P. N., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814. 1998.
17. Oliveira, I. C., Sciavolino, P. J., Lee, T. H., and Vilcek, J. Downregulation of interleukin-8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition of interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053, 1992.
18. Singh, R. K., Gutman, M., Llansa, N., and Fidler, I. J. Interferon-β prevents the up-regulation of interleukin-8 expression in human melanoma cells. J. Interferon Cytokine Res., 16: 577-584, 1996.
19. Fabra, A., Nakajima, M., Bucana, C. D., and Fidler, I. J. Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation, 52: 10I-110, 1992.
20. Gohji, K., Fidler, I. J., Tsan, R., Radinsky, R., von Eschenbach, A. C., Tsuruo, T., and Nakajima, M. Human recombinant interferons β and γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer, 58: 380-384, 1994.
21. Kato, N., Nawa, A., Tamakochi, K., Kikkawa, F., Suganuma, N., Okamoto, T., Goto, S., Tomoda, Y., Hamaguchi, M., and Nakajima, M. Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon-β. Am. J. Obstet. Gynecol., 172: 601-606, 1995.
22. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P. N., and Fidler, I. J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1999.
23. Talpaz, M., Rosenbloom, M., Kurzrock, R., Reuben, J., Kantarjian, H., and Gutterman, J. Clinical and laboratory changes induced by α interferon in chronic lymphocytic leukemia: a pilot study. Am. J. Hematol., 24: 341-350, 1997.
24. Golomb, H., and Ellis, E. Treatment options for hairy-cell leukemia. Semin. Oncol., 18: 7-11, 1991.
25. White, C., Sondheimer, H., Crouch, E., Wilson, H., and Fan, L. Therapy of pulmonary hamangiomatosis with recombinant α-2a. N. Engl. J. Med., 320: 1197-1200, 1989.
26. White, C. W. Treatment of hemangiomatosis with recombinant interferon-α. Semin. Hematol., 27: 15-22, 1990.
27. Ghyka, G., Alecu, M., Halalau, F., and Coman, G. Intralesional human leukocyte interferon treatment alone or associated with IL-2 in non-AIDS related Kaposi's sarcoma. J. Dermatol., 19: 35-39, 1992.
28. Kirn, D. H., and Kramer, A. Long-term freedom from disease progression with interferon α therapy in two patients with malignant hemangiopericytoma. J. Natl. Cancer Inst. (Bethesda), 88: 764-765, 1996.
29. Schiller, J. H., Storer, B., Bittner, G., Willson, J. K., and Borden, E. C. Phase II trial of a combination of interferon-β and interferon-α in patients with advanced malignant melanoma. J. Interferon Res., 8: 581-589, 1988.
30. Strander, H. Interferon treatment of human neoplasia. Adv. Cancer Res., 46: 1-26, 1991.
31. Einhorn, S., and Grander, D. Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res., 16: 275-281, 1996.
32. Gleave, M. E., Elhalali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., and the Canadian Urologic Oncology Group. Interferon γ-1b compared with placebo in metastatic renal-cell carcinoma. N. Engl. J. Med., 338: 1265-1271. 1998.
33. Salmon, P., le Cotonnec, J. Y., Galazka, A., Abdul-Ahad, A., and Darragh, A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-b in healthy male volunteers. J. Interferon Cytokine Res., 16: 758-764, 1996.
34. Fierlbeck, G., Ulmer, A., Schreiner, T., Stroebel, W., Scheible, U., and Brzoska, J. Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma. J. Interferon Cytokine Res., 16: 777-781, 1996.
35. Gutterman, J. Cytokine therapeutics: lessons from interferon-a. Proc. Natl. Acad. Sci. USA, 91: 1198-1205, 1994.
36. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler. I. J. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA, 92: 4562-4566, 1995.
37. Sicca, G., Fabbroni, L., Gastagnetta, L., Cacciatore, M., and Pavone-Macaluso, M. Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol. Res., 17: 111-115, 1989.
38. Muller, B., Fischer, B., and Kreutz. W. An acidic microenvironment impairs the generation of nonmajor histocompatibility complex restricted killer cells. Immunology, 99: 375-384, 2000.
39. Iwata, A., Saito, T., Mizukoshi-Iwata, N., Fujino, M., Katsumata, A., Hamada, K., Sokawa, Y., and Ueda, S. Cloning and expression of the canine interferon-β gene. J. Interferon Cytokine Res., 16: 765-770, 1996.
40. Katayose, D., Gudas, J., Nguyen, H., Srivastava, S., Cowan, K. H., and Seth, P. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin. Cancer Res., 1: 889-897, 1995.
41. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
42. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
43. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J. Expression of angiogenesis-related genes and progression of human ovarian carcinoma in nude mice. J. Natl. Cancer Inst. (Bethesda), 90: 447-454, 1998.
44. Reed, J. A., Manahan, L. J., Park, C. S., and Brigati, D. J. Complete one-hour immunocytochemistry based on capillary action. Biotechniques, 13: 434-443, 1992.
45. Caruthers, M. H., Beaucage, S. L., Efcavitch, J. W., Fisher, E. F., Goldman, R. A., Dehaseth, P. L., Mandechi, W., Matteucci, M. D., Rosendahl, M. S., and Stabinsky, Y. Chemical synthesis and biological studies on mutated gene-control region. Cold Spring Harbor Symp. Quant. Biol., 47: 411-418, 1982.
46. Radinsky, R., Bucana, C. D., Ellis, L. M., Sanchez, R., Cleary, K. R., Brigati, D. J., and Fidler, I. J. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res., 53: 937-943, 1993.
47. Fisher, L. D., and van Belle. G. Biostatistics, pp. 786-843. New York: John Wiley & Sons, 1993.
48. Kelman, Z. PCNA: structure, function, and interactions. Oncogene, 14: 629-640, 1997.
49. Herr, H. W. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) tumors: 15-year outcome. J. Urol., 163: 60-61, 2000.
50. Qin, X. Q., Tao, N., Dergay, A., Moy, P., Fawell, S., Davis, A., Wilson, J. M., and Barsoum, J. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA, 95: 14411-14416, 1998.
51. Sidky, Y. A., and Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47: 5155-5166, 1987.
52. Albini, A., Marchisone, C., Del Grosso, F., Benelli, R., Masiello, L., Tacchetti, C., Bono, M., Ferrantini, M., Rozera, C., Truini, M., Beladelli, F., Santi, L., and Noonan, D. M. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am. J. Pathol., 156: 1381-1393, 2000.
53. Dinney, C. P., Tanguay, S., Bucana, C. D., Eve, B. Y., and Fidler, I. J. Intravesical liposomal muramyl tripeptide phosphotidylethanolamine treatment of human bladder carcinoma growing in nude mice. J. Interferon Cytokine Res., 15: 585-592, 1995.
54. Targan, S., and Dorey, F. Interferon activation of "pre-spontaneous killer" (Pre-Sk) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells. J. Immunol., 124: 2157-2167, 1980.
55. Liu, C. C., Perussia, B., Cohn, Z. A., and Young, J. D. Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells. J. Exp. Med., 164: 2061-2071, 1986.
56. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond.), 339: 58-61, 1989.
57. Folkman, J. How is blood vessel growth regulated in normal and neoplastic tissue? 24th G. H. A. Clowes Memorial Award Lecture. Cancer Res., 46: 467-473, 1986.
58. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
59. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
60. Kirsch, M., Strasser, J., Allende, R., Bello, L., Zhang, J., and Black, P. M. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res., 58: 4654-4659, 1998.
61. Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., Radinsky, R., and Dinney C. P. Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody Imclone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res., 6: 4874-4884, 2000.
62. Li, Y., Pong, R. C., Bergelson, J. M., Hall, M. C., Sagalowski, A. I., Tseng, C. P., Wang, Z., and Hsieh, J. T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res., 59: 325-330, 1999.
63. Connor, R. J., Engler, H., Machemer, T., Philopena, J. M., Horn, M. T., Sutjipto, S., Maneval, D. C., Youngster, S., Chan, T-M., Bausch, J., McAuliffe, J. P., Hindsgaul, O., and Nagabhushan, T. L. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Ther., 8: 41-48, 2001.n